NGL Fine Chem Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹159 Cr +32.5% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
NF

NGL Fine Chem Ltd

Q3 FY26Pharmaceuticals & Biotechnology

NGL Fine Chem Q3 FY26: Revenue ₹127.51 Cr, PAT ₹15.69 Cr

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹128Cr
+43.8% YoY
+6.7% QoQ
Net profit
₹16Cr
+1500% YoY
+60% QoQ
Margin
18%
+12 pp YoY
+4 pp QoQ

Based on NGL Fine Chem Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,895
Market cap₹1.7K Cr
P/E33.9

The short version

Quarterly Revenue (Q3FY26): ₹127.51 crores. EBITDA for Q3FY26: ₹22.31 crores, up 338% YoY.

From NGL Fine Chem Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Quarterly Revenue (Q3FY26): ₹127.51 crores
  • Year-on-Year (Y-o-Y) Revenue Growth: 43.11%
  • Quarterly Revenue (Q3FY25): ₹89.10 crores
  • Revenue from Operations growth (9MFY26 vs 9MFY25): 28.74% (₹351.89 crores vs ₹273.34 crores)
  • Volume drivers: Growth driven primarily by higher volumes across the product portfolio, with price realizations broadly stable (Management commentary on Page 6)

2 more points from NGL Fine Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Greenfield Expansion at Tarapur
  • Larger capacity expansion to drive next growth leg
  • Estimated capex ₹160 crore
  • Funded through debt and internal accrual
  • Civil construction underway
  • Invested ₹156 crore till Q3FY26
  • Phase II commissioning scheduled for Q1FY27
  • Commercial production expected from H2 FY27 after trial and validation batches
  • Total revised investment approx. ₹210 crore
  • Subsidiary Macrotech Expansion
  • Completed expansion with additional intermediate capacities
  • Commercial production started
  • Funding
  • Borrowings capped at approx. ₹85 crore
  • Remaining funding from internal accruals

2 more points from NGL Fine Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Specifically: - Pending or backlog orders are not referenced anywhere in the presentation.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

NGL Fine Chem Ltd Q3 FY26 results — key figures

NGL Fine Chem Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue12889+43.8%120+6.7%
Operating profit (EBITDA)225+340%17+29.4%
Operating margin18%6%+12 pp14%+4 pp
Profit before tax211+2000%13+61.5%
Net profit (PAT)161+1500%10+60%
EPS (₹)25.402.07+1127.1%15.59+62.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were NGL Fine Chem Ltd Q3 FY26 results?

Quarterly Revenue (Q3FY26): ₹127.51 crores. EBITDA for Q3FY26: ₹22.31 crores, up 338% YoY.

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

Greenfield Expansion at Tarapur - Larger capacity expansion to drive next growth leg - Estimated capex ₹160 crore - Funded through debt and internal accrual - Civil construction underway - Invested ₹156 crore till Q3FY26 - Phase II commissioning scheduled for Q1FY27 - Commercial production expected from H2 FY27 after trial and validation batches - Total revised investment approx.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.